NCT07223411 2025-11-26Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic MelanomaUniversity of PittsburghRecruiting20 enrolled
NCT07064330 2025-09-10NGF-GRACEInstituto de Investigación Biomédica de SalamancaRecruiting30 enrolled
NCT06269133 2025-08-27Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) PatientsRegeneron PharmaceuticalsActive not recruiting1,000 enrolled